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The bactericidal/permeability-increasing protein (BPI) inhibits the lipopolysaccharide (LPS)-
mediated activation of monocytes. Due to its inhibitory activity for various LPS, BPI has thera-
peutic potential in endotoxic shock. To be efficient in vivo, BPI should overcome the action of
LPS-binding protein (LBP), a serum molecule that increases the expression of LPS-inducible
genes via CD 14 of monocytes. rBPI23 , a recombinant fragment of BPI, prevented in a dose-de-
pendent manner the binding and the internalization of LPS mediated by LBP. Consequently,
rBPI23 also inhibited LPS-induced tumor necrosis factor (TN Fa) synthesis from monocytes.
LPS- and LBP-mediated activation of monocytes was totally inhibited when LPS was preincu-
bated with rBPI 23 • Adding rBPI23 at the same time as LBP resulted in an important but partial
inhibition of TNFa release, but this inhibition vanished with delaying the time of addition of
rBPI23 • These studies suggest that the inhibitory activity of BPI is related to its ability to compete
with LBP for LPS.
Living organisms have developed several protective mech-
anisms against toxic lipopolysaccharide (LPS) of gram-nega-
tive bacteria. Very recently, two members ofa family of pro-
teins have been recognized that possess LPS-binding sites.
Indeed, the LPS-binding protein (LBP) and the bactericidalf
permeability-increasing protein (BPI) share the ability to
bind to smooth and rough LPS as well as to lipid A [1, 2].
There is a striking homology in the DNA sequence of the two
human, rabbit, or bovine proteins [3]. However, despite their
structural similarities, the functions of LBP and BPI appear
an tagonistic.
Most circulating LPS binds to plasma LBP, and LPS linked
to LBP is transferred to CD 14 on the surface of cells of the
monocytic lineage and neutrophils, resulting in increased ex-
pression of LPS-inducible genes [3, 4]. LBP-mediated pro-
cesses include increased tumor necrosis factor-a (TNFa) pro-
duction by monocytes [3-5], accelerated priming of
neutrophils for the oxidative response to FMLP [6], and in-
creased adhesive capacity of complement receptor CR3 of
neutrophils [7]. LBP was originally described as an acute-
phase reactant in the rabbit [8], but its concentration in nor-
mal serum of rabbits, calves, mice, and humans [5] suggests
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that constitutive LBP is sufficient to bind concentrations of
LPS usually found in infected hosts [4].
BPI, a 55-kDa cationic protein found essentially in the
azurophilic granules of polymorphonuclear leukocytes [9], is
specifically cytotoxic for gram-negative bacteria [10]. Solu-
ble BPI, recombinant BPI, or its 25-kDa N-terminal frag-
ment have been shown to inhibit endotoxin activity by neu-
tralizing LPS, as detected by the inhibition of the proteolytic
cascade in the limulus amebocyte lysate assay, by the inhibi-
tion of the priming of neutrophils by LPS, and by the inhibi-
tion of LPS-mediated production of TNFa by monocytes
[11-13].
Because of the apparent antagonistic properties of these
two proteins that bind LPS, it is important to better define
the respective roles of LBP and BPI in the LPS-induced acti-
vation process, inasmuch as BPI has therapeutic potential in
endotoxic shock. We characterized in vitro the direct compe-
tition between LBP and BPI for binding ofLPS to cells of the
monocytic lineage and investigated the competition between
these two molecules in the activation process of monocytes
resulting in TNFa release.
Materials and Methods
Materials. rBPI23 [2], a human recombinant NlIj-terminal
fragment of BPI possessing LPS-neutralizing activity [14], was
obtained from XOMA (Berkeley, CA). Thaumatin (XOMA),
used as a control protein, has a molecular weight and isoelectric
point similar to rBPI23 [2]. Murine LBP was prepared from
serum. Murine LBP is a 61-kDa molecule that shares NlL-termi-
nal sequence homology and functional properties with rabbit
LBP and is able to present LPS to human monocytes [15]. Rab-
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Figure 1. Effects of recombinant bactericidal/permeability in-
creasing protein (rBPI23) on LPS-binding protein-mediated bind-
ing of fluorescein-labeled Escherichia coli 0 I I I LPS by human pe-
ripheral blood mononuclear cells. Incubation medium contained
4% albumin (A), 10% plasma (B), 10% plasma after CDI4 was
blocked on monocytes with anti-CD 14 monoclonal antibody (C),
or 10% plasma with 10 J.Lg of rBPI23 (D). Fluorescence was assessed
by flow cytometry.
was thus of interest to evaluate whether LPS-BPI complexes
would also bind to CO 14 on monocytes or would interfere
with the LBP-mediated binding of LPS through CD 14. Hu-
man monocytes incubated with 1 Jlg/mL FITC-0 III LPS in
medium containing 4% albumin showed only a modest fluo-
rescence (figure lA). In contrast, when cells were incubated
with FITC-OIII LPS in the presence of 10% plasma, mono-
cytes showed a distinctly brighter fluorescence (figure 1B).
Preincubation of monocytes with MAb MY4 completely
suppressed the plasma-mediated LPS binding (figure 1C) to
the level of control monocytes incubated in the presence of
albumin.
In our observations with 10% plasma, the concentration of
LBP was 2 Jlg/mL. We added rBPI 23 to 10% plasma at a final
concentration of 10 JLg/mL together with FITC-Olli LPS.
The presence of rBPI 23 resulted in a decreased fluorescence
(figure 10) compared with that observed with 10% plasma
alone, indicating that less LPS had bound to monocytes. We
then tested the effect of increasing concentrations of rBPI 23
in 10% plasma containing LBP on FITC-Olil LPS binding
to monocytes, using FITC-0 III LPS concentrations from
10 ng/ml. to 1 JLg/mL, as described [5] (table I). The con-
centration ofrBPI23 required for an efficient inhibition ofthe
plasma-mediated binding of FITC-0 II 1 LPS to monocytes
was dependent on the LPS concentration. With a weight ra-
tio of 10: I (10 JLg/mL rBPI23 with I JLg/mL FITC-O III LPS
or I JLg/mL rBPI23 with 100 ng/rnl. FITC-O Ill), a 75% de-
crease in fluorescence intensity compared to control without
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bits were immunized with purified murine LBP, and immune
IgG was purified by protein G chromatography. A control prepa-
ration of IgG was obtained from a polyclonal rabbit antiserum
raised against murine recombinant interleukin-I.
LPS isolated from Escherichia coli 0 III, either unlabeled or
labeled with fluorescein (FITC-O 111 LPS), was purchased
from Sigma (St. Louis). MY4, a specific monoclonal antibody
(MAb) recognizing human CDI4 [16], was purchased from
Coulter Immunology (Luton, UK).
Plasma was prepared from a pool of donors. The concentra-
tion of LBP in this pool was 20 Jlg/mL as measured by ELISA
[17] (done by P. Tobias, Scripps Clinics, La Jolla, CA).
Test for LPS binding to monocytes. Heparinized human
blood samples obtained from normal donors were used to pre-
pare peripheral blood mononuclear cells (PBMC) by centrifuga-
tion over Ficoll-Paque (Pharrnacia, Uppsala, Sweden). PBMC
( (0 6 ) were incubated with I Jlg (alternatively, 10 or 100 ng) of
FITC-01 11 LPS in I mL of RPMI enriched with 10%plasma or
with 4% albumin as control. For CD 14 blockade, monocytes
were pretreated with 10 Jlg/mL MY4 MAb at 37°C After incu-
bation for I h, the cells were washed twice with cold RPMI and
analyzed using a FACScan flow cytometer with the LYSYS soft-
ware package (Becton Dickinson, Basel, Switzerland). To re-
strict the analysis to monocytes, side scatter parameters were
used for gating of the signal [18].
Confocal laser microscopy. Human monocytes were purified
from PBMC by adherence to plastic in 10%human serum for I h
and recovered using a rubber policeman. Purity was >95% as
assessed by morphology and nonspecific esterase staining.
Monocytes were incubated with I Jlg/mL FITC-0 I 11 LPS in
RPMI containing 4% albumin or 10% plasma for 30 min. After
two washes, they were spun down using a cytocentrifuge (Cyto-
spin 2; Shandon, Basel, Switzerland) for 3 min at 700 rpm.
Slides were mounted in TRIS-glycerin-saline buffer and directly
examined by fluorescence microscopy. Optical slices were gen-
erated in a Laser-Sharp MRC 500 confocal microscope (Bio-
Rad Laboratories, Glattbrugg, Switzerland).
TNFa assays. PBMC (0.5 X (0 6) in 200 JlL of RPMI
enriched with 10% plasma were added to each well of 96-well
flat-bottom microtiter plates (Becton Dickinson). These prepara-
tions were stimulated with unlabeled 0111 LPS at various con-
centrations. Thaumatin or rBPI23 at 10 Jlg/mL was added at
various times relative to LPS exposure in plasma. Supernatants
were collected for TNFa measurements after 4 h of culture at
37°C. Under the conditions used in this study, TNFa release by
lymphocytes present in the PBMC fraction was negligible [19].
The cytotoxic activity of TNFa was measured on WEHI clone
13 cells as described [20, 21].
Results
Effects of rBPIn on the LBP-mediated binding of FITe-
DIll LPS to monocytes. We previously reported that
plasma enhanced the binding of FITC-0 I I I LPS to human
monocytes compared with binding observed with albumin
alone. The enhancement in LPS binding was due to plasma
LBP and was blocked by the MY4 anti-CD 14 MAb [5]. It
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Figu~e 2. E~ects of recombinant bactericidal/permeability in-
creasing protem (rBPI 23 ) on binding of fluorescein-labeled Esche-
richia coli 0 III LPS to human peripheral blood mononuclear cells
after antibody-mediated blockade ofLPS binding protein (LBP) in
plasma. Anti-LBP MAB, rabbit IgG directed against mouse LBP.
Data are fluorescence units measured on monocytes.
o CONTROL PLASMA
• PLASMA + ANTI-LBP MAB
~ ALBUMIN
Table 1. Effect of recombinant bactericidal/permeability increas-
ing protein (rBPI 23 ) on the LPS binding protein (LBP)-mediated
binding of fluorescein-labeled Escherichia coli 0 III LPS to human
peripheral blood mononuclear cells.
LPS concentration (ngjmL)
Medium, rBPln
(~gjmL) 10 100 1000
4k albumin 2.0 2.3 2.4
10'1;· plasma
0 4.2 16.2 40.1
0.1 4.1 16.6 39.9
1.0 2.8 3.6 25.7
10.0 2.0 2.5 9.7
10k plasma + anti-CD 14
monoclonal antibody
a 2.3 2.2 2.5
10 2.1 2.3 2.5
NOTE. Data are mean fluorescence units measured on monocytes in
one experiment. Experiment was repeated many times with similar observa-
tions (data not shown).
ANTI-
CD14
+
+
BPI
+
+
o
FLUORESCENCE UNITS
4 8 12 16
Experiment
NOTE. Data are mean fluorescence units measured on monocytes by
flow cytometry in two separate experiments.
!able 2'. Effect of recombinant bactericidal/permeability increas-
mg protem (rBPI 23) on the binding to peripheral blood mononu-
clear cells of fluorescein-labeled Escherichia coli 0 I I I LPS me-
diated by purified murine LPS-binding protein (LBP).
observed in albumin was seen when rBPI23 was added after
antibody-mediated LBP blockade in plasma. These experi-
ments thus confirmed that rBPI23 did not promote the bind-
ing of FITC-O III LPS to monocytes but rather interfered
with the LBP-mediated binding ofFITC-O III LPS to mono-
cytes.
Effects of competition between purified murine LBP and
rBPI23for the binding ofFITC-Olll LPS to monocytes. We
further investigated whether rBPI 23 could interfere with puri-
fied LBP for FITC-0 I I I LPS binding to monocytes. We
used purified murine LBP for these experiments (table 2).
When I J.Lg of rBPI 23 (43 nM) and I J.Lg of purified murine
LBP (16 nM) were added to monocytes in the presence of
100 ng/rnl. LPS, rBPI 23 suppressed the LBP-mediated bind-
ing of FITC-0 I I I LPS to monocytes.
Effects ofrBPI2J on the internalization ofFITC-Olll LPS
into human monocytes. To distinguish between cell surface
binding and intracellular localization ofLPS, preparations of
adherent monocytes were incubated with FITC-OIII LPS
2
3.1
11.8
12.3
3.2
3.2
15.5
13.9
3.1
4% albumin
I ~g murine LBP
I ~g murine LBP + 100 ng rBPI2J
I ~g murine LBP + I ~g rBPI23
rBPI 23 was observed. By increasing the weight ratio to 100: I
(10 JLg/mL rBPI 23 with 100 ng/rnl. FITC-O III LPS), the
plasma-mediated binding of LPS to monocytes was abol-
ished.
In the presence or absence of rBPI 23 , the observed LPS
binding was totally suppressed by CD 14 blockade by anti-
CD 14 MAb. Control thaumatin did not affect the LBP-me-
diated binding of FITC-O III LPS by human monocytes
(data not shown).
Effect of rBPI23 on the binding ofFITC-Olll LPS to hu-
man monocytes after LBP blockade in plasma. The observa-
tions reported above indicated that rBPI23 inhibited the
plasma-mediated binding ofLPS by monocytes in a dose-de-
pendent manner. When FITC-OIII LPS was used at a 1-
JLg/mL concentration, residual binding was found despite the
presence of 10 JLg/mL rBPI 23 (table I). This binding was
suppressed by CD 14 blockade. We then investigated
whether this residual binding was due to LBP or to BPI. We
used murine plasma for these experiments, because we had
an anti-murine LBP antibody readily available and because
murine LBP is able to present LPS to human CDI4 in a
fashion identical to that of human LBP [5, 15]. LBP was
blocked in murine plasma with a rabbit anti-murine LBP
IgG fraction. An irrelevant rabbit IgG fraction directed
against murine interleukin-I was used as control. In the pres-
ence of control murine plasma, LBP was able to increase the
binding of FITC-0 I I I LPS to human monocytes over that
to control monocytes incubated in albumin (figure 2). This
binding was suppressed by antibody-mediated LBP blockade
and, t.o a lesser extent, by the addition of rBPI23 • The prein-
cubation of monocytes with anti-CD 14 MAb MY 4 sup-
pressed LBP-mediated binding of FITC-0 III LPS. No in-
crease in binding of FITC-0 I I I LPS to monocytes over that
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Figure 3. Effects of recombinant bactericidal/permeability increasing protein (rBPI 23 ) on LPS binding protein (LBP)-mediated internal-
ization of fluorescein-labeled Escherichia coli 0 III LPS by human monocytes. Incubation medium contained 4%albumin (a); 10% human
plasma (b); 10%plasma after pretreatment ofmonocytes with anti-CD 14 monoclonal antibody (c); 10% human plasma and rBPI23 that was
preincubated with LPS for 5 min (d); rBPI 23 added concurrently with 10%plasma and monocytes (e); rBPI 23 added 5 min after mixture of
monocytes, 10%plasma, and LPS (f). Fluorescence of monocytes was visualized in confocal microscope after 1 h of incubation.
and analyzed by confocal microscopy, which allows observa-
tion of subsurface structures. Monocytes were scanned in
depth at various focal planes. Through-focus images were
similar, and figure 3 is representative of one focal plane.
When monocytes were incubated for I h with I Jlg/mL
FITC-OIII LPS in 4% albumin (figure 3a), no fluorescence
was detectable. When incubation medium contained 10%
human plasma, the fluorescence observed was cytoplasmic
(figure 3b). When FITC-OIII LPS was added to anti-
CD 14-treated monocytes in the presence of 10% plasma,
fluorescence was abolished (figure 3c). When FITC-Olll
LPS was preincubated with 10 Jlg/mL rBPI23 before adding
human plasma as a source of LBP, no fluorescence was de-
tectable (figure 3d). However, when rBPI 23 was added at the
same time as plasma LBP (figure 3e) or 5 min thereafter
(figure 3f), the uptake of FITC-O III LPS into monocytes
was only partially prevented. At concentrations < 10 Jlg/mL,
rBPI 23 was unable to suppress the fluorescence in these ex-
periments (data not shown).
Time-dependent inhibition by rBPI23 of the LBP-mediated
binding ofFITC-Olll LPS to human monocytes. We previ-
ously reported that the LBP-mediated binding of FITC-
0111 LPS by monocytes is a rapid process largely completed
in 5-15 min [5]. Thus, in the next set of experiments, we
added rBPI23 at various times relative to FITC-0 I I I LPS
exposure in plasma (figure 4). When LPS was first preincu-
bated with rBPI 23 30 min or 5 min before being added to
monocytes in medium containing plasma, LBP-mediated
binding ofFITC-O III LPS to monocytes was virtually abol-
ished. When LPS and rBPI 23 were added without preincuba-
tion together with monocytes in 10% plasma, rBPI23 was still
able to inhibit LPS binding to monocytes. The addition of
rBPI 23 from 5 to 30 min after the initiation of the reaction of
plasma LBP with FITC-O III LPS progressively reduced the
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Discussion
The focus of this investigation was to assay the direct com-
petition between BPI and LBP for LPS binding to mono-
cytes. Indeed. since BPI appears to be an efficient neutraliz-
ing agent of LPS [11- 13], it should in vivo be able to
overcome the action of LBP, which amplifies the effects of
LPS on both monocytes and neutrophils [3-7].
The experiments were first conducted in plasma contain-
ing LBP using a high LPS concentration (I tLg/mL). By both
flow cytometry and confocal microscopy, we observed that
rBPI 23 • a recombinant Nl-ly-rerminal fragment of BPI [2, 14],
reduced LPS binding to monocytes when added to normal
plasma containing LBP. Low residual LPS binding was ob-
served. which was suppressed by CD I4 blockade. Since bind-
ing of LPS to monocytes in the presence of plasma is me-
diated by the formation of LPS-LBP complexes that bind to
CD 14 receptors [3]. these observations demonstrate that the
small residual LPS binding in the presence of a suboptimal
concentration of rBPI 23 was most likely due to LBP. Thus,
rBPI 23 was able to prevent the formation of LPS-LBP com-
plexes and their subsequent binding to human monocytes,
although the inhibition was not complete at a high concen-
tration of 1 tLg/mL LPS. Furthermore, when LBP in plasma
was functionally blocked by specific antibodies. rBPI23 was
not able to present LPS to CD I4 of monocytes. Confocal
microscopy, which allows the observation of subsurface
structures. confirmed that rBPI 23 prevented the LBP-me-
diated internalization of LPS through CD I4.
At LPS concentrations of 100 and 10 ng/rnl., a 100: I
weight ratio of rBPI 23 to LPS appeared necessary to suppress
the LBP-mediated binding of LPS in plasma. The relative
concentrations of LPS. BPI, and LBP appeared thus to play
an important role. When similar amounts ofrBPI23 (43 nM)
and purified murine LBP ( I6 nM) were added to monocytes
in the presence of 100 ng/mL LPS, rBPI23 appeared able to
completely suppress the LBP-mediated binding of LPS to
monocytes. These data indicate that a 3-fold molar excess of
rBPI 23 has a potent inhibitory effect on LPS in direct compe-
tition with LBP. The concentration ofLBP in pooled plasma
used in these experiments was 20 tLg/mL. as measured by
ELISA [17]. In our observations with 10% plasma, the con-
centration of LBP was 2 tLg/mL, that is. 33 nM. To com-
pletely suppress the LBP-mediated binding of 10 ng/mL
LPS, 10 tLg/mL rBPI 23 , or 430 nM, was necessary. This ob-
servation thus suggests that in plasma at least a IO-fold molar
excess of rBPI 23 should be necessary to overcome totally the
action of LBP.
Our experiments showed in addition that the rBPI2rme-
data not shown) after exposure to LPS resulted in unham-
pered TNFa release compared with that seen in controls in-
cubated with thaumatin.
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inhibitory effect of rBPI 23 . Furthermore, rBPI 23 could not
displace the LBP-mediated binding of FITC-0 I I I LPS.
This was shown by adding rBPI 23 for a period of I h, 1 h after
FITC-0 I I I LPS had reacted with monocytes in 10%
plasma. In this setting, the addition of rBPI 23 for a prolonged
period did not modify the fluorescence pattern (data not
shown). Control thaumatin had no effect on the LBP-me-
diated binding of FITC-O I II LPS by human monocytes.
Effects ofrBPI23 on the LPS-mediated TNFa release by hu-
man nionocvtes in medium containing plasma. Having ob-
served that rBPI 23 efficiently blocked LPS binding in a time-
dependent manner, we added rBPI 2 3 to 10% plasma at
various times relative to LPS exposure, and TNFa was mea-
sured in the supernatants after 4 h (figure 5). When LPS
(either 100 pg/rnl. or 1 ng/mL) was first incubated with
rBPI 23 for 5 min before being added to plasma, virtually no
TNFa was detectable in the supernatant after 4 h. rBPI 23 was
still able to inhibit TNFa production, although partially,
when added together with LPS. This inhibition of TNFa
vanished when LPS concentrations> 1 ng/ml. were used.
Delaying the time of addition of rBPl 23 for 5 min (or more,
Figure 4. Time-dependent inhibition of LPS binding protein
(LBP)-mediated binding of fluorescein-labeled Escherichia coli
0111 LPS (FITC-LPS) by human peripheral blood mononuclear
cells (PBMC) in presence of recombinant bactericidalj
permeability-increasing protein (rBPI n ) . Binding was assessed by
flow cytometry after I h of incubation with FITC-LPS; results are %
of maximal FITC-O III LPS binding in plasma alone.
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Figure 5. Effects of recombi-
nant bactericidal/permeability in-
creasing protein (rBPI23) and of
thaumatin on tumor necrosisfactor
(TNF) release of human peripheral
blood mononuclear cells stimu-
lated with LPS.TNF was measured
by bioassay in supernatants after 4
h of culture. Data are mean + SD
of 5 experiments.
Time of addition of rBPI211nd of thaumatin
relative to LPg exposure
I0 BPI • Thaumatln I
diated inhibition of LBP-LPS binding to monocytes was
more efficient when rBPI 23 could interact with LPS before
in terference with LBP. Indeed, rBPI 23 was unable to reverse
the LBP-mediated binding of LPS to monocytes. This was
observed in experiments using flow cytornetry, confocal mi-
croscopy, and monocyte activation measured by TNFa re-
lease, thus extending and confirming a similar study with the
native nonrecombinant protein [12]. This observation indi-
cated that a concentration of 10 jLg/mL rBPI23 was sufficient
to totally inhibit the production ofTNFa mediated by either
100 pg/rnl. or I ng/mL LPS. rBPI 23 was still able to inhibit
TNFa release when added at the same time as LBP, but the
inhibition was not complete. However, delayed addition of
rBPI 23 respective to LBP failed to inhibit TNFa release, an
observation consistent with the hypothesis that a few min-
utes of interaction of the LPS-LBP complex with monocyte
CD 14 could be sufficient to trigger cytokine production.
In conclusion, under the conditions of our assays-I 0%
plasma containing LBP-we can conclude that rBPI 23 com-
peted with but did not totally suppress the LBP-mediated
effects of LPS. Indeed, if rBPI 23 appeared able to block the
LBP-mediated binding of LPS to monocytes as revealed in
our binding assays, this apparent blockade did not totally
suppress TNFa production. Additional studies should be
done in vitro using whole blood or other sources of LPS to
confirm these observations. Thus, our studies showed that
rBPI 23 was very effective as an inhibitor of LPS on mono-
cytes, provided it was used prophylactically. Further studies
in vivo are needed to investigate whether rBPI23 could over-
come the LPS-mediated activation of the host.
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